John B. Henneman III - Mar 13, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Mar 13, 2024
Transactions value $
$50,009
Form type
4
Date filed
3/14/2024, 08:52 PM
Previous filing
Aug 24, 2023
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Purchase $50K +6.86K +536.36% $7.29 8.14K Mar 13, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Tranche A Warrant Purchase +3.43K 3.43K Mar 13, 2024 Common Stock 3.43K Direct F1, F2, F3
transaction APRE Tranche B Warrant Purchase +3.43K 3.43K Mar 13, 2024 Common Stock 3.43K Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
F2 Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
F3 The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
F4 The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
F5 Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
F6 The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.